Aspire BioPharma is trading at $8.13, down 6.55%, with no clear company-specific catalyst emerging for September 25, 2026.
- The latest identifiable company news was the September 9 authorization of a $10 million share-repurchase program, which predates the decline.
- Broader markets are modestly higher, so market-wide weakness does not explain the move.